{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:07:55Z","timestamp":1790186875007,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008693","name":"Gulf Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02273-3","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T09:22:41Z","timestamp":1775985761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1\u2013based therapies: a retrospective observational study in the United Arab Emirates"],"prefix":"10.1186","volume":"26","author":[{"given":"Salma","family":"Almemari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Almulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Alsarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelofar Sami","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"2273_CR1","unstructured":"International Diabetes Federation. Diabetes facts and figures. Brussels: International Diabetes Federation. 2025. Available from: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/. Accessed 20 Dec 2025."},{"issue":"10","key":"2273_CR2","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.3390\/biomedicines13102376","volume":"13","author":"A Rabiee","year":"2025","unstructured":"Rabiee A, Hossain MA, Poojari A. Adipose tissue insulin resistance: a key driver of metabolic syndrome pathogenesis. Biomedicines. 2025;13(10):2376. https:\/\/doi.org\/10.3390\/biomedicines13102376.","journal-title":"Biomedicines"},{"issue":"1","key":"2273_CR3","doi-asserted-by":"publisher","first-page":"16540","DOI":"10.1186\/s12889-023-16540-8","volume":"24","author":"N Namazi","year":"2024","unstructured":"Namazi N, Moghaddam SS, Esmaeili S, Peimani M, Tehrani YS, Bandarian F, et al. Burden of type 2 diabetes mellitus and its risk factors in North Africa and the Middle East, 1990\u20132019: findings from the Global Burden of Disease Study 2019. BMC Public Health. 2024;24(1):16540. https:\/\/doi.org\/10.1186\/s12889-023-16540-8.","journal-title":"BMC Public Health"},{"key":"2273_CR4","unstructured":"Mordor intelligence. Middle East and Africa glucagon-like peptide-1 (GLP-1) agonists market size & share analysis: growth trends and forecasts (2025\u20132030). Hyderabad (India): Mordor Intelligence. 2025. Available from: https:\/\/www.mordorintelligence.com\/industry-reports\/middle-east-and-africa-glucagon-like-peptide-1-agonists-market. Accessed 20 Dec 2025."},{"issue":"Suppl 1","key":"2273_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5\u201321. https:\/\/doi.org\/10.1111\/dom.13129.","journal-title":"Diabetes Obes Metab"},{"issue":"6706","key":"2273_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.ado5019","volume":"385","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. The benefits of GLP-1 drugs beyond obesity: glucagon-like peptide-1\u2013based medicines have weight loss\u2013independent actions. Science. 2024;385(6706):256\u20138. https:\/\/doi.org\/10.1126\/science.ado5019.","journal-title":"Science"},{"key":"2273_CR7","doi-asserted-by":"publisher","first-page":"1293926","DOI":"10.3389\/fcdhc.2023.1293926","volume":"4","author":"L Ferhatbegovi\u0107","year":"2023","unstructured":"Ferhatbegovi\u0107 L, Mr\u0161i\u0107 D, Maci\u0107-D\u017eankovi\u0107 A. The benefits of GLP-1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc. 2023;4:1293926. https:\/\/doi.org\/10.3389\/fcdhc.2023.1293926.","journal-title":"Front Clin Diabetes Healthc"},{"issue":"12","key":"2273_CR8","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1111\/dom.14160","volume":"22","author":"S Verma","year":"2020","unstructured":"Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487\u201392. https:\/\/doi.org\/10.1111\/dom.14160.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2273_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"2273_CR10","doi-asserted-by":"publisher","unstructured":"Anderson SL, Marrs JC. Tirzepatide for type 2 diabetes. Drugs Context. 2023;12. https:\/\/doi.org\/10.7573\/dic.2023-6-1:2023-6-1.","DOI":"10.7573\/dic.2023-6-1:2023-6-1"},{"issue":"7","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1055\/a-1844-1176","volume":"54","author":"X Guo","year":"2022","unstructured":"Guo X, Zhou Z, Lyu X, Xu H, Zhu H, Pan H, et al. The antiobesity effect and safety of GLP-1 receptor agonists in overweight\/obese patients without diabetes: a systematic review and meta-analysis. Horm Metab Res. 2022;54(7):458\u201371. https:\/\/doi.org\/10.1055\/a-1844-1176.","journal-title":"Horm Metab Res"},{"issue":"8","key":"2273_CR12","doi-asserted-by":"publisher","first-page":"e66280","DOI":"10.7759\/cureus.66280","volume":"16","author":"NT Katole","year":"2024","unstructured":"Katole NT, Salankar HV, Khade AM, Kale JS, Bankar NJ, Gosavi P, et al. The antiobesity effect and safety of GLP-1 receptor agonists in overweight\/obese adolescents without diabetes mellitus: a systematic review and meta-analysis. Cureus. 2024;16(8):e66280. https:\/\/doi.org\/10.7759\/cureus.66280.","journal-title":"Cureus"},{"key":"2273_CR13","doi-asserted-by":"publisher","unstructured":"Gratzl S, Rodriguez PJ, Cartwright BMG, Baker C, Stucky NL, Monitoring report. GLP-1 RA prescribing trends \u2013 September 2024 data [Internet]. 2024. Available from: https:\/\/doi.org\/10.1101\/2024.01.18.24301500. Accessed 20 Dec 2025.","DOI":"10.1101\/2024.01.18.24301500"},{"issue":"10","key":"2273_CR14","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00125-023-05962-z","volume":"66","author":"T Karagiannis","year":"2023","unstructured":"Karagiannis T, Bekiari E, Tsapas A. Socioeconomic aspects of incretin-based therapy. Diabetologia. 2023;66(10):1859\u201368. https:\/\/doi.org\/10.1007\/s00125-023-05962-z.","journal-title":"Diabetologia"},{"issue":"5","key":"2273_CR15","doi-asserted-by":"publisher","first-page":"e60545","DOI":"10.7759\/cureus.60545","volume":"16","author":"M Sallam","year":"2024","unstructured":"Sallam M, Snygg J, Allam D, Kassem R. Shifting the scales: tirzepatide\u2019s breakthrough in obesity management. Cureus. 2024;16(5):e60545. https:\/\/doi.org\/10.7759\/cureus.60545.","journal-title":"Cureus"},{"issue":"1","key":"2273_CR16","doi-asserted-by":"publisher","first-page":"e012940","DOI":"10.1161\/JAHA.119.012940","volume":"9","author":"V Raparelli","year":"2020","unstructured":"Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, et al. Sex differences in cardiovascular effectiveness of newer glucose-lowering drugs added to metformin in type 2 diabetes mellitus. J Am Heart Assoc. 2020;9(1):e012940. https:\/\/doi.org\/10.1161\/JAHA.119.012940.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2273_CR17","doi-asserted-by":"publisher","first-page":"e2457232","DOI":"10.1001\/jamanetworkopen.2024.57232","volume":"8","author":"P Berning","year":"2025","unstructured":"Berning P, Adhikari R, Schroer AE, Jelwan YA, Razavi AC, Blaha MJ, et al. Longitudinal analysis of obesity drug use and public awareness. JAMA Netw Open. 2025;8(1):e2457232. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57232.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2273_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/ANNALS-24-02870","volume":"178","author":"JW Ostrominski","year":"2025","unstructured":"Ostrominski JW, Ortega-Montiel J, Tesfaye H, Alix C, DiCesare E, Cromer SJ, et al. Trends in utilization of glucose- and weight-lowering medications after tirzepatide approval in the United States: a population-based cohort study. Ann Intern Med. 2025;178(5):620\u201333. https:\/\/doi.org\/10.7326\/ANNALS-24-02870.","journal-title":"Ann Intern Med"},{"key":"2273_CR19","unstructured":"Blog IQVIA. IQVIA. Finding the growth engines of the endocrine & metabolic, cardiovascular and CNS markets [Internet]. 2023 Oct 20. Available from: https:\/\/www.iqvia.com\/blogs\/2023\/10\/finding-the-growth-engines-of-the-endocrine. Accessed 20 Dec 2025."},{"key":"2273_CR20","doi-asserted-by":"publisher","first-page":"111045","DOI":"10.1016\/j.diabres.2023.111045","volume":"207","author":"D Abdelmannan","year":"2024","unstructured":"Abdelmannan D, AlBuflasa M, Ajlouni H, Zidan M, Rahman F, Farooqi MH, et al. Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates. Diabetes Res Clin Pract. 2024;207:111045. https:\/\/doi.org\/10.1016\/j.diabres.2023.111045.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"2273_CR21","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1111\/dom.15680","volume":"26","author":"A Buckley","year":"2024","unstructured":"Buckley A, Suliman S, Allum M, Mohammed N, Lessan N, le Roux CW, et al. Real-world use of tirzepatide in the treatment of type 2 diabetes in an Arab population. Diabetes Obes Metab. 2024;26(8):3381\u201391. https:\/\/doi.org\/10.1111\/dom.15680.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2273_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"issue":"8","key":"2273_CR23","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(8):1873\u201388. https:\/\/doi.org\/10.2337\/dci24-0003.","journal-title":"Diabetes Care"},{"key":"2273_CR24","doi-asserted-by":"publisher","first-page":"100162","DOI":"10.1016\/j.obpill.2025.100162","volume":"13","author":"H Guo","year":"2025","unstructured":"Guo H, Yang J, Huang J, Xu L, Lv Y, Wang Y, et al. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: a model-based meta-analysis of placebo-controlled trials. Obes Pillars. 2025;13:100162. https:\/\/doi.org\/10.1016\/j.obpill.2025.100162.","journal-title":"Obes Pillars"},{"issue":"2","key":"2273_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/obesities5020026","volume":"5","author":"M Sallam","year":"2025","unstructured":"Sallam M, Snygg J, Ghandour SE, Sallam M. Efficacy and safety of tirzepatide for weight management in non-diabetic obese individuals: a narrative review. Obesities. 2025;5(2):26. https:\/\/doi.org\/10.3390\/obesities5020026.","journal-title":"Obesities"},{"issue":"2","key":"2273_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/HJH.0000000000003903","volume":"42","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Toh KZX, Teo YH. Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials. J Hypertens. 2025;42(2):290\u2013300. https:\/\/doi.org\/10.1097\/HJH.0000000000003903.","journal-title":"J Hypertens"},{"key":"2273_CR27","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.coph.2023.102355","volume":"69","author":"JC Ribeiro-Silva","year":"2023","unstructured":"Ribeiro-Silva JC, Tavares CAM, Girardi ACC. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms. Curr Opin Pharmacol. 2023;69:102355. https:\/\/doi.org\/10.1016\/j.coph.2023.102355.","journal-title":"Curr Opin Pharmacol"},{"key":"2273_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70063","author":"Y Yang","year":"2025","unstructured":"Yang Y, He L, Han S, Yang N, Liu Y, Wang X, et al. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J Diabetes. 2025. https:\/\/doi.org\/10.1111\/1753-0407.70063.","journal-title":"J Diabetes"},{"issue":"3","key":"2273_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/jpm12030454","volume":"12","author":"E Rentzeperi","year":"2022","unstructured":"Rentzeperi E, Pegiou S, Koufakis T, Grammatiki M, Kotsa K. Sex differences in response to treatment with glucagon-like peptide-1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care. J Pers Med. 2022;12(3):454. https:\/\/doi.org\/10.3390\/jpm12030454.","journal-title":"J Pers Med"},{"issue":"5","key":"2273_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3122\/jabfm.2018.05.180039","volume":"31","author":"SS Bhuyan","year":"2018","unstructured":"Bhuyan SS, Shiyanbola O, Deka P, Isehunwa OO, Chandak A, Huang S, et al. The role of gender in cost-related medication nonadherence among patients with diabetes. J Am Board Fam Med. 2018;31(5):743\u201351. https:\/\/doi.org\/10.3122\/jabfm.2018.05.180039.","journal-title":"J Am Board Fam Med"},{"issue":"12","key":"2273_CR31","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J, et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum. 2021;2(12):e214182. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.4182.","journal-title":"JAMA Health Forum"},{"key":"2273_CR32","doi-asserted-by":"publisher","first-page":"112910","DOI":"10.1016\/j.diabres.2025.112910","volume":"229","author":"SM Sklepinski","year":"2025","unstructured":"Sklepinski SM, Deng Y, Swarna KS, Herrin J, Polley EC, Neumiller JJ, et al. Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025;229:112910. https:\/\/doi.org\/10.1016\/j.diabres.2025.112910.","journal-title":"Diabetes Res Clin Pract"},{"key":"2273_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/DMSO.S518994","volume":"18","author":"K Al-Mahzoum","year":"2025","unstructured":"Al-Mahzoum K, Abdelaziz DH, Alenezi F, Almutairi J, Alsubaiei MK, Alharbi AB, et al. Health beliefs and obesity bias as determinants of attitudes toward the rising tides of GLP-1 medications: Mounjaro and Ozempic. Diabetes Metab Syndr Obes. 2025;18:1389\u2013409. https:\/\/doi.org\/10.2147\/DMSO.S518994.","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02273-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02273-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02273-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T01:58:11Z","timestamp":1779069491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02273-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02273-3","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Gulf Medical University (\n                      Ref. no. IRB-COM-STD-60-Jan-2025\n                      ). As this was a retrospective study using anonymized electronic health records, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish was not applicable, as this study involved retrospective analysis of anonymized electronic health records with no identifiable patient information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}